💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Anastrozole

CHEMBL1399 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
293.4 g/mol
LogP
2.1
Phase
4

An aromatase inhibitor that blocks the enzyme responsible for producing estrogen in postmenopausal women, depriving hormone-sensitive breast cancer cells of their growth signal. It is a standard treatment for early and advanced estrogen receptor-positive breast cancer.

분자량

293.4000 g/mol

LogP

2.10

TPSA

78.30 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Generalized Anxiety Disorder Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H19N5

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
회전 가능 결합

                        
4

                    

                    
                    
                    

                        
무거운 원자

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An aromatase inhibitor that blocks the enzyme responsible for producing estrogen in postmenopausal women, depriving hormone-sensitive breast cancer cells of their growth signal. It is a standard treatment for early and advanced estrogen receptor-positive breast cancer.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Anastrozole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1399.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2187.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.